Filling the need for trusted information on national health issues

Medicaid’s Role in Addressing the Opioid Epidemic

Table 1: State Indicators of Medicaid’s Role in Addressing the Opioid Epidemic
State Opioid Overdose Death Rate per 100,000 (2017) Number of Opioid Overdose Deaths (2017) Medicaid Coverage of MAT Drugs (2018) IMD Exclusion Waiver for SUD Treatment (2019)
Prescription Opioids Heroin Synthetic Opioids
United States 14.9 14,495 15,482 28,466 M – 41, B – 51,
N – 51
21 Approved,
7 Pending
Alabama 9.0 141 125 198 M, B, N No
Alaska 13.9 47 36 37 M, B, N Approved
Arizona 13.5 349 334 267 M, B, N Pending
Arkansas 6.5 116 15 68 B, N No
California 5.3 973 715 536 M, B, N Approved
Colorado 10.0 254 224 112 M, B, N No
Connecticut 27.7 188 425 686 M, B, N No
Delaware 27.8 64 121 178 M, B, N Pending
District of Columbia 34.7 39 127 182 M, B, N No
Florida 16.3 1,133 707 2,126 M, B, N No
Georgia 9.7 513 263 419 M, B, N No
Hawaii 3.4 33 10 N/A M, B, N No
Idaho 6.2 55 23 22 B, N No
Illinois 17.2 494 1,187 1,251 M, B, N Approved
Indiana 18.8 390 327 649 M, B, N Approved
Iowa 6.9 95 61 92 M, B, N No
Kansas 5.1 74 25 32 B, N Approved
Kentucky 27.9 399 269 780 B, N Approved
Louisiana 9.3 161 162 156 B, N Approved
Maine 29.9 75 76 278 M, B, N No
Maryland 32.2 524 522 1,542 M, B, N Approved
Massachusetts 28.2 254 466 1,649 M, B, N Approved
Michigan 21.2 510 783 1,368 M, B, N Pending
Minnesota 7.8 150 111 184 M, B, N Pending
Mississippi 6.4 89 34 81 M, B, N No
Missouri 16.5 226 299 618 M, B, N No
Montana 3.6 22 N/A N/A M, B, N No
Nebraska 3.1 32 N/A 25 B, N Pending
Nevada 13.3 239 94 66 M, B, N No
New Hampshire 34.0 51 28 374 M, B, N Approved
New Jersey 22.0 424 1,085 1,376 M, B, N Approved
New Mexico 16.7 144 144 75 M, B, N Approved
New York 16.1 821 1,356 2,238 M, B, N No
North Carolina 19.8 573 537 1,285 M, B, N Approved
North Dakota 4.8 18 N/A 12 B, N No
Ohio 39.2 854 1,000 3,523 M, B, N Pending
Oklahoma 10.2 226 61 102 M, B, N No
Oregon 8.1 124 124 85 M, B, N No
Pennsylvania 21.2 564 819 1,982 M, B, N Approved
Rhode Island 26.9 74 14 201 M, B, N Approved
South Carolina 15.5 312 153 404 B, N No
South Dakota 4.0 14 N/A 14 M, B, N No
Tennessee 19.3 592 311 590 B, N Pending
Texas 5.1 535 569 348 M, B, N No
Utah 15.5 290 147 92 M, B, N Approved
Vermont 20.0 27 41 77 M, B, N Approved
Virginia 14.8 336 556 829 M, B, N Approved
Washington 9.6 250 306 143 M, B, N Approved
West Virginia 49.6 279 244 618 M, B, N Approved
Wisconsin 16.9 318 414 466 M, B, N Approved
Wyoming 8.7 30 N/A 17 B, N No
NOTE: Overdose deaths by type of opioid are not mutually exclusive and should not be summed. Synthetic opioid deaths do not include deaths due to methadone. Medication-Assisted Treatment (MAT) drugs are: methadone (M), buprenorphine (B), and naltrexone (N). Naltrexone includes both oral and injectable. An IMD (Institution for Mental Disease) is an inpatient facility with over 16 beds.
Sources for this table are available at: http://kff.org/infographic/medicaids-role-in-address-opioid-epidemic.
SOURCES

Total number of individuals with OUD in 2017: KFF analysis of the 2017 National Survey on Drug Use and Health (NSDUH). Note: the total number of individuals with OUD is for those ages 12 and older.

Overdose deaths: KFF State Health Facts, “Opioid Overdose Deaths,” accessed May 2019, https://www.kff.org/state-category/health-status/opioids/. Note: synthetic opioid estimates exclude methadone.

Insurance coverage of nonelderly adults with OUD: KFF analysis of 2017 NSDUH. Note: nonelderly adults are 18-64 years. Other includes Medicare, CHAMPUS, and any other type of health insurance.

Naloxone: KFF State Health Facts, “Medicaid Behavioral Health Services: Naloxone Available in at Least One Formulation Without Prior Authorization,” accessed May 2019, https://www.kff.org/other/state-indicator/medicaid-behavioral-health-services-naloxone-available-in-at-least-one-formulation-without-prior-authorization/.

State coverage of MAT medications: KFF State Health Facts, “Medicaid Behavioral Health Services: Substance Use Disorder (SUD) Services,” accessed May 2019, https://www.kff.org/state-category/medicaid-chip/medicaid-behavioral-health-services/substance-use-disorder-sud-services/.

Number of states covering treatment services: KFF State Health Facts, “Medicaid Behavioral Health Services: Substance Use Disorder (SUD) Services,” accessed May 2019, https://www.kff.org/state-category/medicaid-chip/medicaid-behavioral-health-services/substance-use-disorder-sud-services/.

Insurance coverage and treatment: KFF analysis of 2017 NSDUH. Note: Nonelderly adults are 18 to 64 years. Any treatment includes to receiving treatment at any of the following in the past year: inpatient hospital, residential rehabilitation, outpatient rehabilitation, mental health center, and private doctors’ office.

Table 1 State Indicators of Medicaid’s Role in Addressing the Opioid Epidemic: